Literature DB >> 9691456

Structural characterization of the galactoxylomannan of Cryptococcus neoformans Cap67.

V V Vaishnav1, B E Bacon, M O'Neill, R Cherniak.   

Abstract

The galactoxylomannan (GalXM) obtained from the culture supernatant of an acapsular mutant of Cryptococcus neoformans Cap67 was purified by Concanavalin A affinity, ion-exchange, and gel-filtration chromatographies. The structure of GalXM was determined by methylation analysis and by 1D and 2D NMR spectroscopic studies of the intact polysaccharide and of the oligosaccharide fragments generated by Smith degradation and by acetolysis. GalXM is a complex polysaccharide with an alpha-(1-->6) -galactan backbone. The polysaccharide is branched at c-3 of alternate Gal units of the backbone. C-3 is the point of attachment of the oligosaccharide side chains comprised of alpha-D-Man- (1-->3)-alpha-D-Man-(1-->4)- beta-D-Gal-substituted with zero to three terminal beta-Xyl residues as shown in the following structure: [formula: see text].

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9691456     DOI: 10.1016/s0008-6215(97)10058-1

Source DB:  PubMed          Journal:  Carbohydr Res        ISSN: 0008-6215            Impact factor:   2.104


  49 in total

Review 1.  A yeast under cover: the capsule of Cryptococcus neoformans.

Authors:  Indrani Bose; Amy J Reese; Jeramia J Ory; Guilhem Janbon; Tamara L Doering
Journal:  Eukaryot Cell       Date:  2003-08

2.  Loss of cell wall alpha(1-3) glucan affects Cryptococcus neoformans from ultrastructure to virulence.

Authors:  Amy J Reese; Aki Yoneda; Julia A Breger; Anne Beauvais; Hong Liu; Cara L Griffith; Indrani Bose; Myoung-Ju Kim; Colleen Skau; Sarah Yang; Julianne A Sefko; Masako Osumi; Jean-Paul Latge; Eleftherios Mylonakis; Tamara L Doering
Journal:  Mol Microbiol       Date:  2007-03       Impact factor: 3.501

3.  Galactoxylomannan does not exhibit cross-reactivity in the platelia Aspergillus enzyme immunoassay.

Authors:  Magdia De Jesus; Emily Hackett; Michelle Durkin; Patricia Connolly; Arturo Casadevall; Ruta Petraitiene; Thomas J Walsh; L Joseph Wheat
Journal:  Clin Vaccine Immunol       Date:  2007-03-14

Review 4.  Emerging themes in cryptococcal capsule synthesis.

Authors:  Pardeep Kumar; Meng Yang; Brian C Haynes; Michael L Skowyra; Tamara L Doering
Journal:  Curr Opin Struct Biol       Date:  2011-09-01       Impact factor: 6.809

5.  Pbx proteins in Cryptococcus neoformans cell wall remodeling and capsule assembly.

Authors:  Pardeep Kumar; Christian Heiss; Felipe H Santiago-Tirado; Ian Black; Parastoo Azadi; Tamara L Doering
Journal:  Eukaryot Cell       Date:  2014-02-28

6.  Aggregation of Cryptococcus neoformans by surfactant protein D is inhibited by its capsular component glucuronoxylomannan.

Authors:  J K van de Wetering; F E J Coenjaerts; A B Vaandrager; L M G van Golde; J J Batenburg
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

7.  Capsular localization of the Cryptococcus neoformans polysaccharide component galactoxylomannan.

Authors:  Magdia De Jesus; André Moraes Nicola; Marcio L Rodrigues; Guilhem Janbon; Arturo Casadevall
Journal:  Eukaryot Cell       Date:  2008-10-24

8.  Systematic genetic analysis of virulence in the human fungal pathogen Cryptococcus neoformans.

Authors:  Oliver W Liu; Cheryl D Chun; Eric D Chow; Changbin Chen; Hiten D Madhani; Suzanne M Noble
Journal:  Cell       Date:  2008-10-03       Impact factor: 41.582

9.  Cryptococcus neoformans capsular polysaccharide and exopolysaccharide fractions manifest physical, chemical, and antigenic differences.

Authors:  Susana Frases; Leonardo Nimrichter; Nathan B Viana; Antonio Nakouzi; Arturo Casadevall
Journal:  Eukaryot Cell       Date:  2007-12-21

10.  Cryptococcal xylosyltransferase 1 (Cxt1p) from Cryptococcus neoformans plays a direct role in the synthesis of capsule polysaccharides.

Authors:  J Stacey Klutts; Tamara L Doering
Journal:  J Biol Chem       Date:  2008-03-17       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.